The majority of these studies focus on TN BC due to the lack of targets, although ongoing clinical trials such as PENELOPE-B (NCT01864746) or KATHERINE (NCT01772472) explore new approaches for HR+/HER2− and HER2+ BC, respectively. Here, HR is linked to breast cancer.